Novartis India Limited
Agreement Details
Parties Involved: Novartis India Limited (NIL) and Novartis Healthcare Private Limited (NHPL)
Agreement Type: Exclusive Promotion and Distribution Agreement
Execution Date: September 08, 2026
Purpose: The agreement grants Novartis India Limited exclusive rights to promote and distribute NHPL's retina portfolio in India, specifically comprising the products Accentrix® (ranibizumab) and Pagenax® (brolucizumab).
Strategic Rationale: This agreement supports Novartis India's entry into the ophthalmology therapy area and expands its commercial portfolio.
Financial Terms
Upfront Consideration: Novartis India Limited will pay NHPL an upfront consideration of INR 10 Crores (Indian Rupees Ten Crores).
Corporate Relationships
Shareholding: Nil shareholding between the entities
Related Party Status: The parties are not related to Promoter/Promoter Group/Group Companies in any manner
Related Party Transaction: The transaction does not fall within related party transactions
Arm's Length Basis: Confirmed as arm's length transaction
Additional Terms
No special rights such as right to appoint directors, first right to share subscription, or right to restrict capital structure changes are applicable.
No nominee director appointments or potential conflicts of interest arising from the agreement.